Semaglutide for kidney disease in adults with type 1 diabetes
Treatments studied
Part of Hormones & metabolism, Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 2 study tests semaglutide (a diabetes and weight-related medicine) to see if it can slow or improve diabetic kidney disease in people with type 1 diabetes. You may be able to join if you have type 1 diabetes for at least 5 years and ongoing signs of kidney damage measured in urine tests.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and have type 1 diabetes
- You’ve had type 1 diabetes for at least 5 years
- Your urine test shows ongoing kidney damage (UACR at least 30 mg/g) on the last two results within 3 years
- Your kidney filtration is reduced but not too low (eGFR at least 20 mL/min/1.73m²)
- Your blood pressure and cholesterol medicines are stable for at least 4 weeks before starting, and you’ll keep them stable during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether semaglutide can improve heart and blood-vessel outcomes in people with type 1 diabetes who use an insulin pump or automated insulin delivery. It may help reduce cardiovascular risks, but you must meet several health and medication-safety requirements.
This trial tests whether semaglutide (a diabetes drug) can help protect kidney function in people with type 2 diabetes who already have mild to moderate kidney damage. You will take semaglutide or a placebo and have regular kidney function tests.
This study looks at whether the oral medication semaglutide can help treat chronic kidney disease in people who have both type 2 diabetes and a fatty liver related to metabolism. It aims to see if the drug can improve kidney function and liver health.
This trial tests whether semaglutide (a medicine that helps control blood sugar and weight) can improve outcomes for people with type 1 diabetes who have a higher body weight. It may help if you have had type 1 diabetes for at least 3 years and have a BMI of 30 or more, or 27 or more with a related health problem.
This study looks at whether semaglutide (a diabetes medication) affects belly fat and the liver in people who have both type 2 diabetes and chronic kidney disease. It aims to understand if the drug can improve these health markers even in patients with reduced kidney function.
This trial tests if the drug semaglutide can prevent the development of diabetes in people who have recently had a kidney transplant. It may help those at higher risk for post-transplant diabetes.
Hear when a new Diabetic Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.